| 著者 |
Miwa, Keisuke
Kawasaki, Reina
Shimokawa, Mototsugu
Otsuka, Taiga
Tanaka, Toshimitsu
Fukahori, Masaru
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
| en |
Shimokawa, Hozumi（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Takeshita, Shigeyuki
| en |
Takeshita, Shigeyuki（Personal）
Japanese Red Cross Nagasaki Genbaku Hospital
|
Search repository
Nishikawa, Kazuo
Komori, Azusa
Otsu, Satoshi
細川, 歩
WEKO
33635
e-Rad_Researcher
90432111
| ja |
細川, 歩
宮崎大学
|
| ja-Kana |
ホソカワ, アユム
|
| en |
Hosokawa, Ayumu
University of Miyazaki
|
Search repository
Sakai, Tatsunori
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Honda, Takuya
Taguchi, Hiroki
Tsuneyoshi, Kengo
Fujita, Toshihiro
Sakae, Takahiro
Kawaguchi, Yasunori
| en |
Kawaguchi, Yasunori（Personal）
Asakura Medical Association Hospital
|
Search repository
Shirakawa, Tsuyoshi
| en |
Shirakawa, Tsuyoshi（Personal）
Clinical Hematology Oncology Treatment Study Group
|
Search repository
Mizuta, Toshihiko
Mitsugi, Kenji
|
|
内容記述 |
The significance of third-line chemotherapy (CTx) in unresectable pancreatic cancer (UPC) remains unclear. This study evaluated the therapeutic impact of third-line CTx after nanoliposomal irinotecan and fluorouracil combined with folinic acid (nal-IRI + 5-FU/LV) therapy as second-line CTx for UPC./Between June 2020 and May 2021, 104 patients who received nal-IRI + 5-FU/LV therapy as second-line CTx were retrospectively analyzed for post-discontinuation survival (PDS) and overall survival (OS). Comparisons were made between patients transitioning to third-line CTx and those receiving best supportive care (BSC), using a Cox proportional hazards model adjusted for patient background./Of the cohort, 34 patients received third-line CTx, whereas 61 transitioned to BSC. The median OS from first-line CTx in the third-line CTx group was 18.0 months, with a median OS of 9.7 months from second-line CTx. Adjusted median PDS following second-line CTx was 6.5 months for the third-line CTx group compared to 2.3 months for the BSC group (adjusted hazard ratio 0.16; 95% confidence interval 0.08-0.32; P < 0.01)./Third-line CTx should be actively considered for patients with UPC, as the approach may significantly extend survival in those who can tolerate the treatment. |
fulltext (776 KB)
.png)
